COMMON AND UNCOMMON EGFR MUTATIONS ANALYSIS IN CYTOLOGY AND PLASMA SAMPLES OF TREATMENT-NAIVE LUNG CANCER PATIENTS

Respirology ◽  
2017 ◽  
Vol 22 ◽  
pp. 73-73
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Egfr Mutations ◽  
Plasma Samples ◽  
Lung Cancer Patients ◽  
Treatment Naïve

scholarly journals A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations

Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 114 ◽  
Author(s):  
Jen-Hui Tsou ◽  
Qixin Leng ◽  
Feng Jiang
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Limit Of Detection ◽  
Digital Pcr ◽  
Medical Diagnostics ◽  
Egfr Mutations ◽  
Nucleic Acid Detection ◽  
Great Promise ◽  
Plasma Samples ◽  
Lung Cancer Patients

The detection of EGFR mutations in circulating cell-free DNA can enable personalized therapy for cancer. The current techniques for detecting circulating EGFR mutations are expensive and time-consuming with moderate sensitivity. Emerging CRISPR is revolutionizing medical diagnostics and showing a great promise for nucleic acid detection. This study aims to develop CRISPR-Cas12a as a simple test to sensitively detect circulating EGFR mutations in plasma. Serially diluted samples of DNA containing heterozygous EGFR mutations (L858R and T790M) in wild-type genomic DNA are concurrently tested for the mutations by a CRISPR-Cas12a system and droplet digital PCR (ddPCR). The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours. ddPCR detects the mutations with a limit of detection of 0.05% for more than five hours. Plasma samples of 28 lung cancer patients and 20 cancer-free individuals are tested for the EGFR mutations by CRISPR-Cas12a system and ddPCR. The CRISPR-Cas12a system could detect L858R in plasma of two lung cancer patients whose tissue biopsies are positive for L858R, and one plasma sample of three lung cancer patients whose tissue biopsies are positive for T790M. ddPCR detects L858R in the same two plasm samples, however, does not detect T790M in any of the plasma samples. This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.

scholarly journals Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer Patients

2019 ◽  
Vol 20 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Roger Gejman ◽  
Sergio Gonzalez ◽  
Matias Munoz Medel ◽  
Bruno Nervi ◽  
Cesar Sanchez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Egfr Mutations ◽  
Lung Cancer Patients ◽  
Pathological Characteristics

scholarly journals Comparison of Chief Complaints and Patient-Reported Symptoms of Treatment-Naive Lung Cancer Patients Before Surgery

2021 ◽  
Vol Volume 15 ◽  
pp. 1101-1106
Author(s):  
Yaqian Feng ◽  
Wei Dai ◽  
Yaqin Wang ◽  
Jia Liao ◽  
Xing Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Patient Reported ◽  
Chief Complaints ◽  
Treatment Naïve

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

2019 ◽  
Vol 28 (4) ◽  
pp. 1809-1816
Author(s):  
Johnny M. Hoang ◽  
Navneet Upadhyay ◽  
Dozie N. Dike ◽  
Jaekyu Lee ◽  
Michael L. Johnson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Patient Reported Outcomes ◽  
Lung Cancer Patients ◽  
Patient Reported ◽  
Treatment Naïve

scholarly journals BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

2013 ◽  
Vol 8 (3) ◽  
pp. 295-300 ◽  
Author(s):  
Niki Karachaliou ◽  
Carlota Costa ◽  
Ana Gimenez-Capitan ◽  
Miguel Angel Molina-Vila ◽  
Jordi Bertran-Alamillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Ryo Arai ◽  
Sayo Soda ◽  
Tomoko Okutomi ◽  
Hiroko Morita ◽  
Fumito Ohmi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dendritic Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Lipid Accumulation ◽  
Stage Iii ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Treatment Naïve ◽  
Anticancer Immunity

We studied the subsets of peripheral blood dendritic cells (DCs) and lipid accumulation in DCs to investigate the involvement of DCs in the decreased anticancer immunity of advanced lung cancer patients. We analyzed the population of DC subsets in peripheral blood using flow cytometry. We then determined lipid accumulation in the DCs using BODIPY 650/665, a fluorophore with an affinity for lipids. Compared with healthy controls, the number of DCs in the peripheral blood of treatment-naive cancer patients was significantly reduced. In patients with stage III + IV disease, the numbers of myeloid DCs (mDCs) and plasmacytoid DCs were also significantly reduced. Lipid accumulation in DCs evaluated based on the fluorescence intensity of BODIPY 650/665 was significantly higher in stage III + IV lung cancer patients than in the controls. In the subset analysis, the fluorescence was highest for mDCs. The intracellularly accumulated lipids were identified as triglycerides. A decreased mixed leukocyte reaction was observed in the mDCs from lung cancer patients compared with those from controls. Taken together, the results show that lung cancer patients have a notably decreased number of peripheral blood DCs and their function as antigen-presenting cells is decreased due to their high intracellular lipid accumulation. Thereby, anticancer immunity is suppressed.

Sign in / Sign up

Export Citation Format

Share Document